Results 51 to 60 of about 1,073 (146)

Corticosteroid Pulse Therapy for Graves' Ophthalmopathy Reduces the Relapse Rate of Graves' Hyperthyroidism

Frontiers in Endocrinology, 2020
Background: A course of anti-thyroid drugs (ATD) is the most common first line treatment for Graves' hyperthyroidism. However, hyperthyroidism relapse is frequent (30–70%).
Rosario Le Moli, Pasqualino Malandrino, Marco Russo, Fabrizio Lo Giudice, Francesco Frasca, Antonino Belfiore, Riccardo Vigneri, Riccardo Vigneri   +7 more
doaj   +1 more source

Glymphatic System Dysfunction in Thyroid‐Associated Ophthalmopathy: A Multimodal MRI Study

CNS Neuroscience &Therapeutics, Volume 31, Issue 11, November 2025.
TAO patients exhibit impaired glymphatic function, with reduced DTI‐ALPS indices and gBOLD‐CSF coupling, but unchanged choroid plexus volume. These alterations correlate with neuropsychological symptoms and sleep disturbances. Restoring glymphatic activity may offer a therapeutic approach to enhance patient outcomes.
Lijie Zhang, Jiaqi Yao, Yiming Qi, Yongheng Luo, Jun Liu   +4 more
wiley   +1 more source

British Thyroid Association Survey of Graves' Disease Management in the UK

Clinical Endocrinology, Volume 103, Issue 3, Page 376-384, September 2025.
ABSTRACT Background Recent years have seen changes and uncertainties in evidence and guideline recommendations in Graves' disease treatment. To understand the impact of these developments on current practice, we undertook a survey of Graves' disease management in the United Kingdom and compared this to other national and international surveys.
Michael Atkinson, Medha Agrawal, Koteshwara Muralidhara, Prakash Abraham, Bijay Vaidya, Onyebuchi E. Okosieme   +5 more
wiley   +1 more source

Sustainability of Teprotumumab Efficacy in Thyroid Eye Disease

, 2022
Teprotumumab, an insulin-like growth factor-I receptor inhibitory antibody, improved proptosis, diplopia, inflammatory signs/symptoms, and quality of life in thyroid eye disease (TED) patients in phase 2 and 3 (OPTIC) trials.1,2 OPTIC proptosis non ...
Prem S. Subramanian; Saba Sile; Robert Holt; Raymond Douglas
core   +2 more sources

Efficacy of rituximab in treating steroid-resistant Graves’ orbitopathy in active moderate-to-severe and sight-threatening forms: A retrospective observation from China

Heliyon
Background and objectives: The efficacy of rituximab (RTX) in treating steroid-resistant Graves’ orbitopathy (GO) has been limitedly studied in Asians.
Ziyin Zhang, Xiaohui Feng, Yaoyao Guo, Xiaonan Kang, Dan Wang, Jing Zhang, Zhixuan Zeng, Gang Yuan   +7 more
doaj   +1 more source

The Relationship between Obesity-Related Factors and Graves’ Orbitopathy: A Pilot Study

Medicina, 2022
Background and Objectives: The aim of this study was to investigate the relationships between obesity-related factors including body mass index (BMI), diabetes or prediabetes, hyperlipidemia, fasting plasma glucose, fasting plasma insulin, homeostasis ...
Ching Lu, Chao-Lun Lai, Chih-Man Yang, Karen Chia-Wen Liao, Chie-Shung Kao, Tien-Chu Chang, Ming-Der Perng   +6 more
doaj   +1 more source

Embolization of Thyroid Arteries as a Bridge Therapy Before Thyroidectomy in a Patient With Thyrotoxicosis: Case Report [PDF]

Case Reports in Endocrinology
Thyroid artery embolization (TAE) is a minimally invasive technique that induces selective ischemic necrosis of the thyroid parenchyma, thereby reducing thyroid hormone synthesis with few associated complications. Successful cases of TAE as a bridge therapy before total thyroidectomy in patients with refractory thyrotoxicosis are rare.
Gomez-Fontalvo C, Díaz–Jaimes S, Rangel–Villamizar M, Moreno-Diaz D, Castellanos-Bueno R.   +4 more
europepmc   +2 more sources

Radiological Activity Score (RAS)—MRI Characteristics in Dysthyroid Optic Neuropathy in a Multi‐Ethnic Thyroid Eye Disease Population

Clinical Endocrinology, Volume 103, Issue 3, Page 385-395, September 2025.
ABSTRACT Purpose Dysthyroid Optic Neuropathy (DON) is a sight threatening and diagnostically challenging complication of Thyroid Eye Disease (TED). We provide a comparative analysis of the MRI features associated between patietnts with and without DON. Methods Anonymised retrospective cohort study of patients with TED over eleven years.
Malik Moledina, Vickie Lee, Kunwar Bhatia, Gitta Madani, Claire Feeney, Nicole George, Nour Houbby, Daisy Metcalf, Natalie Man, Rajni Jain, Ahmad Aziz, Ravi Kumar Lingam   +11 more
wiley   +1 more source

Orbitopatía tiroidea: protocolo de manejo basado en revisión de la evidencia

Revista Colombiana de Endocrinología, Diabetes y Metabolismo, 2019
La orbitopatía tiroidea es una patología potencialmente grave que amenaza la visión. Es la manifestación extratiroidea más frecuente de la enfermedad de Graves y, aunque la prevalencia no está evaluada en Colombia, puede producir pérdida de la visión ...
C. Gómez, A. Imitola, L. B. Taboada, D. C. Henao, L. F. Marín, J. Camargo, L. Kattath, C. Fonseca, C. Colón, P. Ascnher   +9 more
doaj   +1 more source

Resolution of Thyroid Acropachy in a Patient Treated With Teprotumumab: A Case Report and Review of Mechanisms

Case Reports in Endocrinology, Volume 2025, Issue 1, 2025.
Graves’ disease is an autoimmune thyroidopathy associated with hyperthyroidism and nonendocrine manifestations such as thyroid eye disease (TED), pretibial myxedema, and thyroid acropachy. Thyroid acropachy is an uncommon but debilitating condition, typically characterized by digital clubbing, soft tissue swelling, and periosteal new bone formation in ...
Soumya Chatterjee, Toshihiro Kita
wiley   +1 more source